PURPOSE: To test whether pharmacologic inhibition of ribonucleotide reductase (RNR) by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) enhances radiation sensitivity during low-dose-rate ionizing radiation provided by a novel purpose-built iridium-192 cell irradiator. METHODS AND MATERIALS: The cells were exposed to low-dose-rate radiation (11, 23, 37, 67 cGy/h) using a custom-fabricated cell irradiator or to high-dose-rate radiation (330 cGy/min) using a conventional cell irradiator. The radiation sensitivity of human cervical (CaSki, C33-a) cancer cells with or without RNR inhibition by 3-AP was evaluated using a clonogenic survival and an RNR activity assay. Alteration in the cell cycle distribution was monitored using flow cytometry. RESULTS: Increasing radiation sensitivity of both CaSki and C33-a cells was observed with the incremental increase in radiation dose rates. 3-AP treatment led to enhanced radiation sensitivity in both cell lines, eliminating differences in cell cytotoxicity from the radiation dose rate. RNR blockade by 3-AP during low-dose-rate irradiation was associated with low RNR activity and extended G(1)-phase cell cycle arrest. CONCLUSIONS: We conclude that RNR inhibition by 3-AP impedes DNA damage repair mechanisms that rely on deoxyribonucleotide production and thereby increases radiation sensitivity of human cervical cancers to low-dose-rate radiation.
PURPOSE: To test whether pharmacologic inhibition of ribonucleotide reductase (RNR) by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) enhances radiation sensitivity during low-dose-rate ionizing radiation provided by a novel purpose-built iridium-192 cell irradiator. METHODS AND MATERIALS: The cells were exposed to low-dose-rate radiation (11, 23, 37, 67 cGy/h) using a custom-fabricated cell irradiator or to high-dose-rate radiation (330 cGy/min) using a conventional cell irradiator. The radiation sensitivity of human cervical (CaSki, C33-a) cancer cells with or without RNR inhibition by 3-AP was evaluated using a clonogenic survival and an RNR activity assay. Alteration in the cell cycle distribution was monitored using flow cytometry. RESULTS: Increasing radiation sensitivity of both CaSki and C33-a cells was observed with the incremental increase in radiation dose rates. 3-AP treatment led to enhanced radiation sensitivity in both cell lines, eliminating differences in cell cytotoxicity from the radiation dose rate. RNR blockade by 3-AP during low-dose-rate irradiation was associated with low RNR activity and extended G(1)-phase cell cycle arrest. CONCLUSIONS: We conclude that RNR inhibition by 3-AP impedes DNA damage repair mechanisms that rely on deoxyribonucleotide production and thereby increases radiation sensitivity of human cervical cancers to low-dose-rate radiation.
Authors: H Hayakawa; A Hofer; L Thelander; S Kitajima; Y Cai; S Oshiro; H Yakushiji; Y Nakabeppu; M Kuwano; M Sekiguchi Journal: Biochemistry Date: 1999-03-23 Impact factor: 3.162
Authors: Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella Journal: Clin Cancer Res Date: 2010-02-09 Impact factor: 12.531
Authors: R A Finch; M Liu; S P Grill; W C Rose; R Loomis; K M Vasquez; Y Cheng; A C Sartorelli Journal: Biochem Pharmacol Date: 2000-04-15 Impact factor: 5.858
Authors: Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella Journal: Radiat Res Date: 2010-09-10 Impact factor: 2.841
Authors: Charles A Kunos; Tomas Radivoyevitch; Adam Kresak; Dawn Dawson; James Jacobberger; Bin Yang; Fadi W Abdul-Karim Journal: Int J Gynecol Cancer Date: 2012-11 Impact factor: 3.437
Authors: Stuart G Jarrett; Marian Novak; Sandrine Dabernat; Jean-Yves Daniel; Isabel Mellon; Qingbei Zhang; Nathan Harris; Michael J Ciesielski; Robert A Fenstermaker; Diane Kovacic; Andrzej Slominski; David M Kaetzel Journal: Cancer Res Date: 2011-11-11 Impact factor: 12.701
Authors: Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati Journal: Gynecol Oncol Date: 2013-04-18 Impact factor: 5.482
Authors: Charles A Kunos; Kathryn Winter; Adam P Dicker; William Small; Fadi W Abdul-Karim; Dawn Dawson; Anuja Jhingran; Richard Valicenti; Joanne B Weidhaas; David K Gaffney Journal: Int J Gynecol Cancer Date: 2013-05 Impact factor: 3.437
Authors: Sanath R Wijerathna; Md Faiz Ahmad; Hai Xu; James W Fairman; Andrew Zhang; Prem Singh Kaushal; Qun Wan; Jianying Kiser; Chris G Dealwis Journal: Pharmaceuticals (Basel) Date: 2011-10-13
Authors: Payel Chatterjee; Gaurav S Choudhary; Arishya Sharma; Kamini Singh; Warren D Heston; Jay Ciezki; Eric A Klein; Alexandru Almasan Journal: PLoS One Date: 2013-04-02 Impact factor: 3.240